Effect of low-dose oral contraceptives on metabolic risk factors in African-American women

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 6, 2008, Pages 2097-2103

  Frempong, Barbara A ^a   Ricks, Madia ^a   Sen, Sabyasachi ^a   Sumner, Anne E ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLESE; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; MICROGESTIN; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG RESEARCH; FEMALE; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MAJOR CLINICAL STUDY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 45149084138     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2599     Document Type: Article

References (40)

1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ 2004 Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 1-36
2. David PS, Boatwright EA, Tozer BS 2006 Hormonal contraception update. Mayo Clin Proc 81:949-954
3. Godsland IF, Crook D, Wynn V 1992 Clinical and metabolic considerations of long-term oral contraceptive use. Am J Obstet Gynecol 166(6 Pt 2):1955-1963
4. Piper JM, Kennedy DL 1987 Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol 16:215-221
5. Baillargeon JP, McClish DK, Essah PA, Nestler JE 2005 Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90:3863-3870
6. Chasan-Taber L, Stampfer MJ 1998 Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 128:467-477
7. Dinger JC, Heinemann LA, Kuhl-Habich D 2007 The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75:344-354
8. 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA [Erratum (1995) 274:1676] 273:199-208
9. Hulley S, Grady D, Bush T 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
10. Manson JE, Hsia J, Johnson KC, Roussow JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534
11. Manson JE, Allison MA, Rossouw JE 2007 Estrogen therapy and coronary-artery calcification. N Engl J Med 356:2591-2602
12. Nicholson WK, Brown AF, Gathe J, Grumbach K, Washington AE, Perez-Stable EJ 1999 Hormone replacement therapy for African-American women: missed opportunities for effective intervention. Menopause 6:147-155
13. Weng HH, McBride CM, Bosworth HB, Grambow SC, Siegler IC, Bastian LA 2001 Racial differences in physician recommendation of hormone replacement therapy. Prev Med 33:668-673
14. Russell-Briefel R, Ezzati TM, Perlman JA, Murphy RS 1987 Impaired glucose tolerance in women using oral contraceptives: United States, 1976-1980. J Chronic Dis 40:3-11
15. Watanabe RM, Azen CG, Roy S, Perlman JA, Bergman RN 1994 Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab 79:1277-1283
16. Simon D, Senan C, Garnier P 1990 Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: the Telecom study. Am J Obstet Gynecol 163(1 Pt 2):382-387
17. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V 1992 Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74:64-70
18. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW 2006 Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29:1263-1268
19. Sumner AE, Cowie CC 2008 Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 196:696-703
20. Palaniappan LP, Carnethon MR, Fortmann SP 2002 Heterogeneity in the relationship between ethnicity, BMI, and fasting insulin. Diabetes Care 25:1351-1357
21. Sumner AE, Farmer NM, Cochran CS 2001 Obese premenopausal African-American women with normal and impaired glucose tolerance have a similar degree of insulin resistance but differ in beta-cell function. Diabetes Care 24:1978-1983
22. Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC 2005 Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 165:1395-1400
23. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN 2003 MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003-1015
24. Kahn SE, Prigeon RL, McCulloch DK 1993 Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663-1672
25. Duffy TJ, Ray R 1984 Oral contraceptive use: prospective follow-up ofwomen with suspected glucose intolerance. Contraception 30:197-208
26. Harvengt C 1992 Effect of oral contraceptive use on the incidence of impaired glucose tolerance and diabetes mellitus. Diabete Metab 18:71-77
27. DECODE Study Group, the European Diabetes Epidemiology Group 2001 Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405
28. Coutinho M, Gerstein HC, Wang Y, Yusuf S 1999 The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240
29. Sheu WH, Hsu CH, Chen YS, Jeng CY, Fuh MM 1994 Prospective evaluation of insulin resistance and lipid metabolism in women receiving oral contraceptives. Clin Endocrinol (Oxf) 40:249-255
30. van Genugten RE, Utzschneider KM, Tong J, Gerchman F, Zraika S, Udayasankar J, Boyko EJ, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group 2006 Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes. Diabetes 55:3529-3535
31. De Pirro R, Forte F, Bertoli A, Greco AV, Lauro R 1981 Changes in insulin receptors during oral contraception. J Clin Endocrinol Metab 52:29-33
32. Bertoli A, De Pirro R, Fusco A, Greco AV, Magnatta R, Lauro R 1980 Differences in insulin receptors between men and menstruating women and influence of sex hormones on insulin binding during the menstrual cycle. J Clin Endocrinol Metab 50:246-250
33. Krauss RM, Burkman Jr RT 1992 The metabolic impact of oral contraceptives. Am J Obstet Gynecol 167(4 Pt 2):1177-1184
34. Sondheimer SJ 1991 Update on the metabolic effects of steroidal contraceptives. Endocrinol Metab Clin North Am 20:911-923
35. Sharrett AR, Ballantyne CM, Coady SA 2001 Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108-1113
36. Hokanson JE, Austin MA 1996 Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219
37. Sarwar N, Danesh J, Eiriksdottir G 2007 Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450-458
38. Petersen KR 2002 Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 49:43-60
39. Godsland IF, Crook D, Wynn V 1991 Coronary heart disease risk markers in users of low-dose oral contraceptives. J Reprod Med 36(Suppl):226-237
40. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators 2007 Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med [Erratum (2007) 357:835] 356:1304-1316